Aura Biosciences Virtual Ocular Oncology Investor Event to Discuss Phase 2 End of Study Data Evaluating Bel-sar in Early-Stage Choroidal Melanoma
DATE: | September 12, 2024 |
---|---|
TIME: | 8:00 AM EDT |
LOCATION: | Virtual |
About The Event
Join Aura Biosciences for a virtual ocular oncology investor event featuring Dr. Ivana Kim, MD (Mass Eye and Ear) and Dr. Prithvi Mruthyunjaya, MD, MHS (Stanford University Byers Eye Institute) to discuss the Phase 2 end of study data evaluating suprachoroidal administration of bel-sar (AU-011) for the first-line treatment of patients with small choroidal melanoma and indeterminate lesions. A live question and answer session will follow the formal discussion.
The Phase 2 results will also be presented at The Retina Society Annual Meeting being held September 11-15, 2024, in Lisbon, Portugal. The presentation details are as follows:
Title: Final Results of a Phase 2 Trial of Suprachoroidal Administration of Belzupacap Sarotalocan (bel-sar, AU-011) for Choroidal Melanoma
Presenter: Dr. Ivana Kim, MD, Mass Eye and Ear
Date/Time: Thursday, September 12, 2024, from 11:04 am to 11:09 am Western European Daylight Time (6:04 am to 6:09 am Eastern Time)